JAZZ PHARMACEUTICALS PLC (JAZZ) Fundamental Analysis & Valuation

NASDAQ:JAZZ • IE00B4Q5ZN47

Current stock price

199.92 USD
-4.06 (-1.99%)
At close:
196.11 USD
-3.81 (-1.91%)
After Hours:

This JAZZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. JAZZ Profitability Analysis

1.1 Basic Checks

  • JAZZ had positive earnings in the past year.
  • JAZZ had a positive operating cash flow in the past year.
  • In multiple years JAZZ reported negative net income over the last 5 years.
  • In the past 5 years JAZZ always reported a positive cash flow from operatings.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • With a decent Return On Assets value of -3.05%, JAZZ is doing good in the industry, outperforming 74.35% of the companies in the same industry.
  • The Return On Equity of JAZZ (-8.25%) is better than 76.96% of its industry peers.
  • The Return On Invested Capital of JAZZ (4.34%) is better than 82.20% of its industry peers.
  • JAZZ had an Average Return On Invested Capital over the past 3 years of 5.00%. This is significantly below the industry average of 13.10%.
Industry RankSector Rank
ROA -3.05%
ROE -8.25%
ROIC 4.34%
ROA(3y)1.75%
ROA(5y)0.1%
ROE(3y)5.51%
ROE(5y)0.19%
ROIC(3y)5%
ROIC(5y)3.72%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15 20

1.3 Margins

  • The Operating Margin of JAZZ (12.13%) is better than 83.77% of its industry peers.
  • In the last couple of years the Operating Margin of JAZZ has declined.
  • JAZZ's Gross Margin of 88.21% is amongst the best of the industry. JAZZ outperforms 91.62% of its industry peers.
  • In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
Industry RankSector Rank
OM 12.13%
PM (TTM) N/A
GM 88.21%
OM growth 3Y59.74%
OM growth 5Y-11.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.15%
GM growth 5Y-1.2%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. JAZZ Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
  • The number of shares outstanding for JAZZ has been increased compared to 1 year ago.
  • JAZZ has more shares outstanding than it did 5 years ago.
  • JAZZ has a better debt/assets ratio than last year.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 1.79, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
  • JAZZ has a Altman-Z score (1.79) which is in line with its industry peers.
  • The Debt to FCF ratio of JAZZ is 4.68, which is a neutral value as it means it would take JAZZ, 4.68 years of fcf income to pay off all of its debts.
  • JAZZ's Debt to FCF ratio of 4.68 is amongst the best of the industry. JAZZ outperforms 83.77% of its industry peers.
  • A Debt/Equity ratio of 1.00 is on the high side and indicates that JAZZ has dependencies on debt financing.
  • JAZZ has a worse Debt to Equity ratio (1.00) than 76.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 4.68
Altman-Z 1.79
ROIC/WACC0.61
WACC7.11%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 1.86 indicates that JAZZ should not have too much problems paying its short term obligations.
  • The Current ratio of JAZZ (1.86) is worse than 67.54% of its industry peers.
  • A Quick Ratio of 1.67 indicates that JAZZ should not have too much problems paying its short term obligations.
  • The Quick ratio of JAZZ (1.67) is worse than 63.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.67
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. JAZZ Growth Analysis

3.1 Past

  • JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.30%.
  • JAZZ shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -8.04% yearly.
  • Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.88% in the last year.
  • JAZZ shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.54% yearly.
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
Revenue 1Y (TTM)4.88%
Revenue growth 3Y5.26%
Revenue growth 5Y12.54%
Sales Q2Q%10.09%

3.2 Future

  • Based on estimates for the next years, JAZZ will show a very strong growth in Earnings Per Share. The EPS will grow by 31.62% on average per year.
  • JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.26% yearly.
EPS Next Y195.57%
EPS Next 2Y76.16%
EPS Next 3Y50.51%
EPS Next 5Y31.62%
Revenue Next Year4.86%
Revenue Next 2Y6.26%
Revenue Next 3Y6.97%
Revenue Next 5Y7.26%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

8

4. JAZZ Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 24.38, the valuation of JAZZ can be described as rather expensive.
  • Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 80.63% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of JAZZ to the average of the S&P500 Index (26.54), we can say JAZZ is valued inline with the index average.
  • With a Price/Forward Earnings ratio of 8.25, the valuation of JAZZ can be described as very reasonable.
  • JAZZ's Price/Forward Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 93.19% of the companies in the same industry.
  • JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.68.
Industry RankSector Rank
PE 24.38
Fwd PE 8.25
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • JAZZ's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. JAZZ is cheaper than 84.82% of the companies in the same industry.
  • 89.53% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 10.74
EV/EBITDA 11.68
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60

4.3 Compensation for Growth

  • JAZZ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as JAZZ's earnings are expected to grow with 50.51% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y76.16%
EPS Next 3Y50.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAZZ Dividend Analysis

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ Fundamentals: All Metrics, Ratios and Statistics

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (4/29/2026, 8:24:38 PM)

After market: 196.11 -3.81 (-1.91%)

199.92

-4.06 (-1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength49.32
Industry Growth58.67
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners102.46%
Inst Owner Change0.63%
Ins Owners2.59%
Ins Owner Change2.04%
Market Cap12.31B
Revenue(TTM)4.27B
Net Income(TTM)-356.15M
Analysts85.22
Price Target228.13 (14.11%)
Short Float %8.81%
Short Ratio5.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.27%
Min EPS beat(2)-0.11%
Max EPS beat(2)34.65%
EPS beat(4)1
Avg EPS beat(4)-9.11%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-4.44%
EPS beat(12)4
Avg EPS beat(12)-4.44%
EPS beat(16)6
Avg EPS beat(16)-10.63%
Revenue beat(2)1
Avg Revenue beat(2)0.16%
Min Revenue beat(2)-0.43%
Max Revenue beat(2)0.75%
Revenue beat(4)1
Avg Revenue beat(4)-3.11%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.75%
Revenue beat(8)2
Avg Revenue beat(8)-2.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.02%
Revenue beat(16)3
Avg Revenue beat(16)-2.1%
PT rev (1m)1.94%
PT rev (3m)3.26%
EPS NQ rev (1m)1.69%
EPS NQ rev (3m)-0.07%
EPS NY rev (1m)-2.78%
EPS NY rev (3m)5.57%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)0.24%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-1.11%
Valuation
Industry RankSector Rank
PE 24.38
Fwd PE 8.25
P/S 2.88
P/FCF 10.74
P/OCF 9.08
P/B 2.85
P/tB N/A
EV/EBITDA 11.68
EPS(TTM)8.2
EY4.1%
EPS(NY)24.24
Fwd EY12.12%
FCF(TTM)18.62
FCFY9.31%
OCF(TTM)22.02
OCFY11.02%
SpS69.32
BVpS70.15
TBVpS-31.52
PEG (NY)0.12
PEG (5Y)N/A
Graham Number113.768 (-43.09%)
Profitability
Industry RankSector Rank
ROA -3.05%
ROE -8.25%
ROCE 5.5%
ROIC 4.34%
ROICexc 5.86%
ROICexgc 57.11%
OM 12.13%
PM (TTM) N/A
GM 88.21%
FCFM 26.85%
ROA(3y)1.75%
ROA(5y)0.1%
ROE(3y)5.51%
ROE(5y)0.19%
ROIC(3y)5%
ROIC(5y)3.72%
ROICexc(3y)6.52%
ROICexc(5y)4.68%
ROICexgc(3y)48.58%
ROICexgc(5y)33.56%
ROCE(3y)6.33%
ROCE(5y)4.72%
ROICexgc growth 3Y116.75%
ROICexgc growth 5Y-3.48%
ROICexc growth 3Y83.19%
ROICexc growth 5Y-11.56%
OM growth 3Y59.74%
OM growth 5Y-11.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.15%
GM growth 5Y-1.2%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF 4.68
Debt/EBITDA 3.57
Cap/Depr 30.12%
Cap/Sales 4.92%
Interest Coverage 2.08
Cash Conversion 111.69%
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.67
Altman-Z 1.79
F-Score5
WACC7.11%
ROIC/WACC0.61
Cap/Depr(3y)14.71%
Cap/Depr(5y)26.3%
Cap/Sales(3y)2.41%
Cap/Sales(5y)4.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
EPS Next Y195.57%
EPS Next 2Y76.16%
EPS Next 3Y50.51%
EPS Next 5Y31.62%
Revenue 1Y (TTM)4.88%
Revenue growth 3Y5.26%
Revenue growth 5Y12.54%
Sales Q2Q%10.09%
Revenue Next Year4.86%
Revenue Next 2Y6.26%
Revenue Next 3Y6.97%
Revenue Next 5Y7.26%
EBIT growth 1Y-29.56%
EBIT growth 3Y68.14%
EBIT growth 5Y0.13%
EBIT Next Year219.18%
EBIT Next 3Y49.09%
EBIT Next 5Y32.24%
FCF growth 1Y-14.97%
FCF growth 3Y13.99%
FCF growth 5Y17.11%
OCF growth 1Y-2.88%
OCF growth 3Y2.15%
OCF growth 5Y8.55%

JAZZ PHARMACEUTICALS PLC / JAZZ Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 5 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 8 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


What is the profitability of JAZZ stock?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 5 / 10.


What is the valuation of JAZZ PHARMACEUTICALS PLC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 24.38 and the Price/Book (PB) ratio is 2.85.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 195.57% in the next year.